report | Audio Medica – Medical Audio News Interviews & Podcasts

Audio Journal of Oncology Volume 16 Number 11+

3rd June 2008

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)

Sarah Maxwell and Peter Goodwin report from: American Society of Clinical Oncology Annual Meeting, May 30-June 3, 2008, Chicago

Michael Gnant

In this edition:

1. Zoledronic …

Read More+

Risks From Stopping Cancer Trials Early!+

9th April 2008

Giovanni Apolone

In this edition of Audio News, presented by Peter Goodwin, Giovanni Apolone (Mario Negri Institute, Milan) and Stuart Pocock (London School of Hygiene and Tropical Medicine), talk about:

Risks From Stopping Cancer Trials Early!
- A report from

…

Read More+

Radio-Labelled Antibodies: Big Benefits in Follicular Lymphoma?+

27th February 2008

Timothy Illidge

Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
TIMOTHY ILLIDGE, Christie Hospital, Manchester
Radioconjugated antibodies are showing great promise for treating follicular lymphoma which has failed chemotherapy combined with rituximab. That’s according to Tim

…

Read More+

Adjuvant Chemoradiotherapy: Big Gains In Pancreas Cancer+

27th January 2008

Charles Hsu

CHARLES HSU, Johns Hopkins University, Baltimore
Big improvements in overall survival were achieved by combining radiation with adjuvant chemotherapy for patients with pancreas cancer in a dtudy reported to the conference in Orlando. Charles Hsu told Peter Goodwin

…

Read More+

Live Report from ASH:
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma+

11th December 2007

anton hagenbeek Live Report from ASH:<br />Ibritumomab Provides Benefit in Patients with Follicular Lymphoma” src=”http://www.audiomedica.com/img/asco/071209/anton_hagenbeek.jpg” /<br /> Anton Hagenbeek </div>
</p>
</div>
<div>
<div>
<strong> ANTON HAGENBEEK, University Medical Centre Utrecht </strong><br />
For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah </div>
</div>
<p>…</p></div>
<!--END .post-content -->

</div>

<a class=

Read More+

Live Report from ASH:
Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?+

11th December 2007

christian geisler Live Report from ASH:<br />Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?” src=”http://www.audiomedica.com/img/asco/071211/christian_geisler.jpg” /<br /> Christian Geisler </div>
</p>
</div>
<div>
<div>
<strong> CHRISTIAN GEISLER, Rigshospitalet, Copenhagen </strong><br />
Mantle cell lymphoma, which was previously considered incurable, has apparently been cured in some patients on a phase II study. Derek Thorne got the details </div>
</div>
<p>…</p></div>
<!--END .post-content -->

</div>

<a class=

Read More+

Live Report from ASH:
Oblimersen Extends Survival in Chronic Lymphocytic Leukemia+

10th December 2007

$susan o brien Live Report from ASH:<br />Oblimersen Extends Survival in Chronic Lymphocytic Leukemia” src=”http://www.audiomedica.com/img/asco/071209/susan_o_brien.jpg” /<br /> Susan O’Brien </div> </p> </div> <div> <div> <strong> SUSAN O’BRIEN, MD Anderson Cancer Center, Houston </strong><br /> For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. <strong>Susan O’Brien</strong> presented data from this </div> </div> <p>…</p></div>  </div> <a class=$ Read More+

Live Report from ASH:
Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML+

10th December 2007

richard stone Live Report from ASH:<br />Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML” src=”http://www.audiomedica.com/img/asco/071209/richard_stone.jpg” /<br /> Richard Stone </div>
</p>
</div>
<div>
<div>
<strong> RICHARD STONE, Dana-Farber Cancer Institute, Boston<br />
GEORGE CANELLOS, Dana-Farber Cancer Institute</strong><br />
New data shows that dasatinib is giving durable responses in patients with chronic phase </div>
</div>
<p>…</p></div>
<!--END .post-content -->

</div>

<a class=

Read More+

Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes+

10th December 2007

Pierre Fenaux

PIERRE FENAUX, Paris 13 University
Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University

…

Read More+

Live Report from ASH:
Interleukin-2 For Acute Myeloid Leukemia In First Remission?+

10th December 2007

jonathan kolitz Live Report from ASH:<br />Interleukin 2 For Acute Myeloid Leukemia In First Remission?” src=”http://www.audiomedica.com/img/asco/071209/jonathan_kolitz.jpg” /<br /> Jonathan Kolitz </div>
</p>
</div>
<div>
<div>
<strong>JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY<br />
GEORGE CANELLOS, Dana-Farber Cancer Institute</strong><br />
For patients with acute myeloid leukemia in first remission, new data suggests that there </div>
</div>
<p>…</p></div>
<!--END .post-content -->

</div>

<a class=

Read More+

TRITON-TIMI 38 Prasugrel Or Clopidogrel In Percutaneous Intevention?+

5th November 2007

Gordon Tomaselli
daniel jones TRITON TIMI 38 Prasugrel Or Clopidogrel In Percutaneous Intevention?

Daniel Jones

REFERENCE: Late Breaking Clinical Trials 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
GORDON TOMASELLI, Johns Hopkins University, Baltimore
COMMENT: DANIEL JONES, President, American Heart Association, University of Mississippi, Jackson
A potential new

…

Read More+

BORIS: A. baumanni Highly Resistant β-Lactamase and Varying Susceptibility Patterns+

21st September 2007

jane hata team BORIS: A. baumanni Highly Resistant β Lactamase and Varying Susceptibility Patterns

Jennifer Lavrrar, Jane Hata, Jeanette Block

REFERENCE: Slide Session C2-1360, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
JANE HATA, bioMéríeux Inc, Durham
Reports from the BORIS study call for ongoing surveillance of multi-drug resistant Acinetobacter

…

Read More+

5 posts remaining + Load More